Apr 11, 2022 / 07:00PM GMT
Michael Stephen Matson - Needham & Company, LLC, Research Division - Senior Analyst
Good afternoon, everyone. Thanks for joining us at the 21st Annual Needham Healthcare Conference. I'm Mike Matson, and I lead the Medtech [and Lead] Research team here at Needham & Company. With me is Penumbra's CEO, Adam Elsesser; and Executive Vice President of Strategy, Jason Mills. Instead a standard presentation, we are going to do a Q&A session. (Operator Instructions)
So we're going to go straight into the Q&A here.
Questions and Answers:
Michael Stephen Matson - Needham & Company, LLC, Research Division - Senior AnalystI just want to start off with some questions on the Vascular business. Obviously, that's been a tremendous success story for Penumbra, very, very strong growth over the last few years, despite the pandemic.
So just in terms of this growth, I was wondering if you could maybe just talk about what's been driving it? And is it really just simply an under-penetrated market and procedures being converted from tPA
Trustpilot
